Search
Clobetasone
go.drugbank.com/drugs/DB13158ApprovedClobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions … Topical clobetasone butyrate has shown minimal suppression of the Hypothalamic-pituitary-adrenal axis.
Estazolam
go.drugbank.com/drugs/DB01215ApprovedIllicitInvestigationalIt has been shown in some cases to be more potent than diazepam or nitrazepam.
Chlordiazepoxide
go.drugbank.com/drugs/DB00475ApprovedIllicitIt has also been used in the symptomatic treatment of alcohol withdrawal.
Fluorodopa (18F)
go.drugbank.com/drugs/DB13848ApprovedInvestigationalFluorodopa F 18 is a fluorinated analog of [levodopa] used as a diagnostic agent for positron emission tomography (PET) in the evaluation of Parkinsonian syndromes.
Copper oxodotreotide Cu-64
go.drugbank.com/drugs/DB15873Approved[A220348] In a head-to-head trial, the former tracer detected twice as many lesions as the latter.[A220348] … [A220348] Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution.
Nilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigationalNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). … ), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Lurbinectedin
go.drugbank.com/drugs/DB12674ApprovedInvestigationalLurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma,[A214325] chronic lymphocytic leukemia (CLL),[A214328] breast cancer, … Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[L48501] The European Commission also approved the marketing of etrasimod on February 19, 2024.[L50998] … [A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis.
Colistin
go.drugbank.com/drugs/DB00803ApprovedInvestigationalIt is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes.
Flortaucipir F-18
go.drugbank.com/drugs/DB14914ApprovedInvestigationalwell as to regions containing high levels of melanin, neuromelanin, and iron. … [A203933] It is used as a marker in positron emission tomography (PET) imaging of patients suspected of having Alzheimer's disease.